Indivior PLC Ordinary Shares (INDV) Stock: Buy, Sell, or Hold?
INDV - Indivior PLC Ordinary Shares
$34.49
-0.02 (-0.06%)
▼
5d:
-0.98%
30d:
-10.95%
90d:
-9.55%
BUY
HIGH Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Get Alerted When INDV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INDV appears deeply undervalued. Market expects -10.8% annual earnings decline despite 600% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: INDV appears deeply undervalued. Market expects -10.8% annual earnings decline despite 600% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$69.69
Based on 7.4% avg growth
INTRINSIC VALUE TODAY
$43.27
20.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INDV is currently trading at $34.49, which is considered oversold relative to its 30-day fair value range of $34.95 to $38.54. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.1) compared to its historical average (10.0). Remarkably, the market is currently pricing in an annual earnings decline of 10.8% over the next few years. This pessimistic expectation contrasts with the company's recent 600% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INDV is in a strong uptrend. The price is currently testing key support at $33.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INDV scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $49.00 (+42.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INDV is in a strong uptrend. The price is currently testing key support at $33.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INDV scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $49.00 (+42.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$34.95 -
$38.54
Company Quality Score
69/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (78/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.1% below Wall St target ($49.00)
- BULLISH: Bottoming setup score 78/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$34.95 -
$38.54
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$33.84
Resistance Level
$35.49
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.06
Wall Street Target
$49.00
(+42.1%)
Revenue Growth (YoY)
13.6%
Earnings Growth (YoY)
600.0%
Profit Margin
26.8%
Valuation Discount vs History
-10.8% cheaper
PE vs Historical
7.1 vs 10.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.8%
(market-implied from PE analysis)
1-Year Target
$31.04
(-10%)
2-Year Target
$27.94
(-19%)
3-Year Target
$25.14
(-27%)
3-Yr Target (if PE normalizes)
(PE: 7→10)
$35.60
(+3%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 10.8%)
$133.85
(+288%)
Base:
(SPY PE: 7.1, Growth: 10.8%)
$46.87
(+36%)
Bear:
(PE: 6.0, Growth: 10.8%)
$39.84
(+16%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 12.46 | Current EPS (TTM): $2.77
Bull Case
$66.92
(+94%)
Analyst growth 76.3%, PE expands to 13.7
Base Case
$60.84
(+76%)
Market implied 76.3%, PE stable at 12.5
Bear Case
$23.47
(-32%)
Severe decline -20.0%, PE contracts to 10.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.1 to 10.0
Stabilization Target:
$48.83
(+41.6%)
PE Expansion Potential:
+41.6%
Share & Embed Analysis
Last updated: September 12, 2026 9:08 PM ET
Data refreshes hourly during market hours. Next update: 10:08 PM
Data refreshes hourly during market hours. Next update: 10:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INDV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
Advanced INDV Option Strategies
Professional options setups generated by AI based on today's INDV price and gamma walls.
